Showing results (331-340 of 887) with videos related to
Sort By:
Pageof 89
Circulation Research|January 17, 2015
Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosisKevin M Patel, Alanna Strong, Junichiro Tohyama, et al.Coronary Artery Disease|March 17, 2004
Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemiaDonald B Hunninghake, Evan A Stein, Harold E Bays, et al.Pharmacogenetics and Genomics|June 20, 2017
Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapySony Tuteja, Lu Wang, Richard L Dunbar, et al.Lipids|April 30, 2014
Lipidomic analyses of female mice lacking hepatic lipase and endothelial lipase indicate selective modulation of plasma lipid speciesYanbo Yang, Takashi Kuwano, William R Lagor, et al.European Heart Journal|January 14, 2016
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyJohn J P Kastelein, Steven E Nissen, Daniel J Rader, et al.Human Gene Therapy|September 19, 2012
Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemiaSadik H Kassim, Hui Li, Peter Bell, et al.Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Evaluation of the genome-informed risk assessment (GIRA) approach from eMERGE in an independent health systemSandra Lapinska, Xinzhe Li, Ravi Mandla, et al.Nature Communications|March 22, 2021
Disrupting upstream translation in mRNAs is associated with human diseaseDavid S M Lee, Joseph Park, Andrew Kromer, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|November 13, 2010
Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in miceEric T Alexander, Charulatha Vedhachalam, Sandhya Sankaranarayanan, et al.Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.Pageof 89